Our aim has always been to push the boundaries of what technology is able to produce, and we are proud to hold a proprietary technology, named ESiNAR-X^®, that gives us a unique advantage compared to the rest of the industry. The platform covers unconventional structural design of oligonucleotide-based inhibitors to significantly improve their characteristics in many ways.

The inhibitors based on the ESiNAR-X^® platform show:

The progressiveness of the ESiNAR-X^® platform is underlined by its theoretical applicability to any diagnosis with a known genetic causality and/or unmet need. The already shown unmatched accuracy in target recognition resulting in the fascinating possibility of eliminating off-target related side effects may facilitate the implementation of this platform not only in clinical practice, but also for research and technology purposes.